Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism - a prospective, randomized, controlled study

Clinical Transplantation

Volumn 27, Issue 3, 2013, Pages

  Chen, Si Yang ^a   Li, Jia Li ^b   Meng, Fan Hang ^c   Wang, Xue Ding ^b   Liu, Tao ^b   Li, Jun ^a   Liu, Long Shan ^a   Fu, Qian ^a   Huang, Min ^b   Wang, Chang Xi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cytochrome P450 3A5; Diltiazem; Gene polymorphism; Individualization; Tacrolimus

Indexed keywords

CREATININE; CYTOCHROME P450 3A5; DILTIAZEM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; ENZYME POLYMORPHISM; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HYPERLIPIDEMIA; INDIVIDUALIZATION; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NEW ONSET DIABETES AFTER TRANSPLANTATION; OPEN STUDY; PARALLEL DESIGN; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; CLINICAL TRIAL; DOSE RESPONSE; GENETIC POLYMORPHISM; GENETICS; GRAFT REJECTION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; PERSONALIZED MEDICINE; PROGNOSIS; TISSUE DISTRIBUTION;

ADULT; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALIZED MEDICINE; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; TACROLIMUS; TISSUE DISTRIBUTION;

EID: 84878665075     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12101     Document Type: Article

References (30)

1. Venkataramanan R, Swaminathan A, Prasad T et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995: 29: 404.
2. Leroy S, Isapof A, Fargue S et al. Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics. Pediatr Nephrol 2010: 25: 965.
3. Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999: 33: 680.
4. Jones TE, Morris RG. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002: 41: 381.
5. El-Dahshan KF, Bakr MA, Donia AF, Badr Ael S, Sobh MA. Ketoconazole-tacrolimus coadministration in kidney transplant recipients: two-year results of a prospective randomized study. Am J Nephrol 2006: 26: 293.
6. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004: 43: 623.
7. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 1999: 290: 1116.
8. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009: 9(Suppl 3): S1.
9. Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008: 18: 861.
10. Chandel N, Aggarwal PK, Minz M, Sakhuja V, Kohli KK, Jha V. CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole. Pharmacogenet Genomics 2009: 19: 458.
11. Hustert E, Haberl M, Burk O et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001: 11: 773.
12. De Jonge H, Kuypers DR. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant Rev (Orlando) 2008: 22: 6.
13. Li JL, Wang XD, Chen SY et al. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Pharmacogenomics J 2011: 11: 300.
14. Iordanous Y, Seymour N, Young A et al. Recipient outcomes for expanded criteria living kidney donors: the disconnect between current evidence and practice. Am J Transplant 2009: 9: 1558.
15. Li JL, Wang XD, Wang CX et al. Rapid and simultaneous determination of tacrolimus (FK506) and diltiazem in human whole blood by liquid chromatography-tandem mass spectrometry: application to a clinical drug-drug interaction study. J Chromatogr B Analyt Technol Biomed Life Sci 2008: 867: 111.
16. Loparev VN, Cartas MA, Monken CE, Velpandi A, Srinivasan A. An efficient and simple method of DNA extraction from whole blood and cell lines to identify infectious agents. J Virol Methods 1991: 34: 105.
17. Wang Y, Wang C, Li J et al. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Eur J Clin Pharmacol 2009: 65: 239.
18. Renders L, Frisman M, Ufer M et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007: 81: 228.
19. Hesselink DA, Van Schaik RH, Van Der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003: 74: 245.
20. Haufroid V, Wallemacq P, Van Kerckhove V et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 2006: 6: 2706.
21. Zhao Y, Song M, Guan D et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc 2005: 37: 178.
22. Tirelli S, Ferraresso M, Ghio L et al. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients. Med Sci Monit 2008: 14: CR251.
23. Bensoussan C, Delaforge M, Mansuy D. Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem Pharmacol 1995: 49: 591.
24. Yamaori S, Yamazaki H, Iwano S et al. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 2004: 19: 120.
25. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui K. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 2006: 16: 119.
26. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001: 27: 383.
27. Canaparo R, Finnstrom N, Serpe L et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 2007: 34: 1138.
28. Von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004: 75: 172.
29. Thervet E, Loriot MA, Barbier S et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010: 87: 721.
30. Jusko WJ, Piekoszewski W, Klintmalm GB et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995: 57: 281.